Medication adherence and complementary therapy usage in inflammatory bowel disease patients during the coronavirus disease 2019 pandemic.
Alex BarnesJane AndrewsPaul SpizzoRéme MountifieldPublished in: JGH open : an open access journal of gastroenterology and hepatology (2021)
Even in the setting of low COVID-19 prevalence, the pandemic reduced IBD medication adherence in 1 in 20 patients. This reduced adherence was co-associated with increased disease activity and corticosteroid use. Understanding the underlying beliefs driving suboptimal IBD medication adherence is critical to prevent avoidable adverse IBD outcomes.
Keyphrases
- coronavirus disease
- end stage renal disease
- sars cov
- disease activity
- rheumatoid arthritis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- emergency department
- risk factors
- rheumatoid arthritis patients
- adipose tissue
- skeletal muscle
- glycemic control
- weight loss
- juvenile idiopathic arthritis